BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 11120510)

  • 1. Continuous combined hormone replacement therapy and risk of endometrial cancer.
    Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
    Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
    Beresford SA; Weiss NS; Voigt LF; McKnight B
    Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
    McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL
    Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and endometrial cancer.
    Emons G; Huschmand-Nia A; Krauss T; Hinney B
    Onkologie; 2004 Apr; 27(2):207-10. PubMed ID: 15138357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
    Doherty JA; Cushing-Haugen KL; Saltzman BS; Voigt LF; Hill DA; Beresford SA; Chen C; Weiss NS
    Am J Obstet Gynecol; 2007 Aug; 197(2):139.e1-7. PubMed ID: 17689625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of endometrial cancer following estrogen replacement with and without progestins.
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
    J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States).
    Green PK; Weiss NS; McKnight B; Voigt LF; Beresford SA
    Cancer Causes Control; 1996 Nov; 7(6):575-80. PubMed ID: 8932917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
    Reed SD; Voigt LF; Beresford SA; Hill DA; Doherty JA; Weiss NS
    Am J Obstet Gynecol; 2004 Oct; 191(4):1146-51. PubMed ID: 15507934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestogen deficiency and endometrial cancer risk.
    Schindler AE
    Maturitas; 2009 Apr; 62(4):334-7. PubMed ID: 19231117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Menopausal hormone use and endometrial cancer, by tumor grade and invasion.
    Shapiro JA; Weiss NS; Beresford SA; Voigt LF
    Epidemiology; 1998 Jan; 9(1):99-101. PubMed ID: 9430277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
    Persson I; Weiderpass E; Bergkvist L; Bergström R; Schairer C
    Cancer Causes Control; 1999 Aug; 10(4):253-60. PubMed ID: 10482483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008.
    Fournier A; Dossus L; Mesrine S; Vilier A; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
    Am J Epidemiol; 2014 Sep; 180(5):508-17. PubMed ID: 25008104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.